Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography

被引：12

作者：

Hutchinson, OC ^{[1
]}

Collingridge, DR ^{[1
]}

Barthel, H ^{[1
]}

Price, PM ^{[1
]}

Aboagye, EO ^{[1
]}

机构：

[1] Hammersmith Hosp, Imperial Coll Sch Med, Sec Canc Therapeut, CRC PET Oncol Grp, London W12 0NN, England

来源：

CURRENT PHARMACEUTICAL DESIGN | 2003年 / 9卷 / 11期

关键词：

D O I：

10.2174/1381612033455288

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Positron emission tomography (PET) provides the oncologist with information on tumour diagnosis, and treatment response monitoring. Mathematical modelling of tissue data, and online plasma radioactive metabolite profiling, enables important tissue kinetic parameters relating to the uptake, distribution and washout as well as arterial input function to be derived. The resultant kinetic data allow for not only diagnosis but also the assessment of therapeutic response endpoints. These endpoints can be used to measure specific therapeutic effects. This novel application of PET can provide information that is often difficult to measure in the intact animal or patient. The pharmacokinetics of radiolabelled N - [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA), temozolomide and 5-fluorouracil (5-FU) are described.

引用

页码：917 / 929

页数：13

共 82 条

[1] POTENTIAL ANTITUMOR AGENTS .57. 2-PHENYLQUINOLINE-8-CARBOXAMIDES AS MINIMAL DNA-INTERCALATING ANTITUMOR AGENTS WITH INVIVO SOLID TUMOR-ACTIVITY [J].

ATWELL, GJ ;

BAGULEY, BC ;

DENNY, WA .

JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (02) :396-401

[2] POTENTIAL ANTITUMOR AGENTS .50. INVIVO SOLID-TUMOR ACTIVITY OF DERIVATIVES OF N-[2-(DIMETHYLAMINO)ETHYL]ACRIDINE-4-CARBOXAMIDE [J].

ATWELL, GJ ;

REWCASTLE, GW ;

BAGULEY, BC ;

DENNY, WA .

JOURNAL OF MEDICINAL CHEMISTRY, 1987, 30 (04) :664-669

[3]

BAGULEY BC, 1992, ONCOL RES, V4, P267

[4] DESIGN OF DNA INTERCALATORS TO OVERCOME TOPOISOMERASE II-MEDIATED MULTIDRUG RESISTANCE [J].

BAGULEY, BC ;

HOLDAWAY, KM ;

FRAY, LM .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (05) :398-402

[5] CANCER-RESEARCH CAMPAIGN PHASE-II TRIAL OF TEMOZOLOMIDE IN METASTATIC MELANOMA [J].

BLEEHEN, NM ;

NEWLANDS, ES ;

LEE, SM ;

THATCHER, N ;

SELBY, P ;

CALVERT, AH ;

RUSTIN, GJS ;

BRAMPTON, M ;

STEVENS, MFG .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) :910-913

[6] Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma [J].

Bower, M ;

Newlands, ES ;

Bleehen, NM ;

Brada, M ;

Begent, RJH ;

Calvert, H ;

Colquhoun, I ;

Lewis, P ;

Brampton, MH .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 40 (06) :484-488

[7]

BRADY F, 1991, APPL RADIAT ISOTOPES, V42, P621

[8] Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET [J].

Brady, F ;

Luthra, SK ;

Brown, GD ;

Osman, S ;

Aboagye, E ;

Saleem, A ;

Price, PM .

CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (18) :1863-1892

[9] New strategy developments in brain tumor therapy [J].

Brandes, AA ;

Basso, U ;

Pasetto, LM ;

Ermani, M .

CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (16) :1553-1580

[10] Intra- and extracellular fluorouracil uptake: Assessment with contrast-enhanced metabolic F-19 MR imaging [J].

Brix, G ;

Bellemann, ME ;

Gerlach, L ;

Haberkorn, U .

RADIOLOGY, 1998, 209 (01) :259-267

← 1 2 3 4 5 6 7 8 9 →